EGFR and lung cancer: Because the de novo prevalence of MET amplification [44,45] and overlap by verifying degrees with other oncogenic drivers [46] are confounding factors that need to be studied in greater detail, our MET ISH results for EGFR-TKI-resistant lung cancer have clinical relevance in routine practice.